Duke Cancer Institute ( Site 4120)

Durham, North Carolina 27710

0 studies enrolling now · 2 studies all time

What they study most

Cervical Cancer, Endometrial Cancer

Studies at this site

• A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) — Running, not enrolling
• Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) — Running, not enrolling